[1]王永军,张云,石良静,等.百令胶囊联合前列地尔对糖尿病肾病患者炎症因子及肝肾功能的影响[J].西部中医药,2022,35(06):115-117.[doi:10.12174/j.issn.2096-9600.2022.06.28]
　WANG Yongjun,ZHANG Yun,SHI Liangjing,et al.Influence of Bailing Capsules and Alprostadil on Inflammatory Factors, Liver and Renal Function in Patients with Diabetic Nephropathy[J].Western Journal of Traditional Chinese Medicine,2022,35(06):115-117.[doi:10.12174/j.issn.2096-9600.2022.06.28]
点击复制

百令胶囊联合前列地尔对糖尿病肾病患者炎症因子及肝肾功能的影响
分享到：

《西部中医药》[ISSN:2096-9600/CN:62-1204/R]

卷:
35
期数:
2022年06期
页码:
115-117
栏目:
衷中参西
出版日期:
2022-06-15

文章信息/Info

Title:
Influence of Bailing Capsules and Alprostadil on Inflammatory Factors, Liver and Renal Function in Patients with Diabetic Nephropathy
作者:
王永军1, 张云2, 石良静1, 吕培1, 宫磊1, 左志瑶1, 刘建震1
1.河北省胸科医院，河北 石家庄 050041
2.河北省南和县人民医院
Author(s):
WANG Yongjun1, ZHANG Yun2, SHI Liangjing1, LYU Pei1, GONG Lei1, ZUO Zhiyao1, LIU Jianzhen1
1.Hebei Chest Hospital, Shijiazhuang 050041, China
2.Nanhe County People′s Hospital
关键词:
糖尿病肾病; 百令胶囊; 前列地尔; 炎症因子; 肝肾功能
Keywords:
diabetic nephropathy; capsules; alprostadil; inflammatory factors; liver and renal function
分类号:
R587.2
DOI:
10.12174/j.issn.2096-9600.2022.06.28
文献标志码:
B
摘要:
目的观察百令胶囊联合前列地尔对糖尿病肾病（diabetic nephropathy，DN）患者炎症因子及肝肾功能的影响。 方法选择102例DN患者，应用随机数字表法分为观察组和对照组，每组51例。对照组接受前列地尔治疗；观察组接受百令胶囊联合前列地尔治疗。疗程4个月。观察两组临床疗效，炎症因子指标［白介素6（interleukin 6，IL-6）、肿瘤坏死因子α（tumor necrosis factor-α，TNF-α）］，肝肾功能指标［血肌酐（serum creatinine，Scr）、尿素氮（blood urea nitrogen，BUN）、β2-微球蛋白（β2-microglobulin，β2-MG）］，肾脏纤维化指标［Ⅳ型胶原（collagenⅣ，CⅣ）、血浆层黏蛋白（laminin，LN）、Ⅲ型前胶原（procollagenⅢ，PCⅢ）］及血糖指标［（fasting plasma glucose，FPG）、糖化血红蛋白（HemoglobinA1c，HbA1c）、餐后2小时血糖（2-hour postprandial blood glucose，2hPG）］变化情况。 结果观察组总有效率［90.20%（46/51）］高于对照组［74.51%（38/51）］（P＜0.05）。治疗后，两组IL-6、TNF-α、Scr、β2-MG、UAER、CⅣ、LN、PCⅢ、FPG、HbA1c、2hPG水平均较治疗前降低（P＜0.05），且观察组低于对照组（P＜0.05）。 结论DN患者接受百令胶囊联合前列地尔治疗可行性较高，可降低患者炎症因子水平，改善肾功能，抑制肾脏纤维化进程。
Abstract:
ObjectiveTo observe the effects of Bailing capsules and alprostadil on inflammatory factors, liver and renal function in patients with DN. MethodsA total of 102 DN patients were selected, divided into the observation group and the control group, with 51 cases in each group, according to random number table method. The control group was treated by alprostadil, and the observation group by Bailing capsules and alprostadil. the course was four months. To observe clinical effects, the indexes of inflammatory factor [IL-6,TNF-α], the indi-cators of liver and renal function [Scr, BUN and β2-MG], the indexes of renal fibrosis [CⅣ, LN and PCⅢ] and the indexes of blood glucose [FPG, HbA1c, 2hPG] between both groups. ResultsTotal effective rare of the observation group was [90.20%(46/51)], higher than [74.51%(38/51)] of the control group (P<0.05). After treatment, the levels of IL-6, TNF-α, Scr, β2-MG, UAER, CⅣ, LN, PCⅢ, FPG, HbA1c and 2hPG lowered in both groups compared with these before treating (P<0.05), and the observation group was lower than the control group (P<0.05). ConclusionIt is feasible for DN patients to take Bailing capsules and alprostadil which could lower the levels of inflammatory factors, improve renal function and inhibit the progression of renal fibrosis.

相似文献/References:

[1]林晓芬,黄燕璇.益肾汤联合厄贝沙坦及胰激肽原酶治疗早期糖尿病肾病的疗效观察[J].西部中医药,2013,26(07):68.
　LIN Xiaofen,HUANG Yanxuan.Clinical Observation on YiShenTang Combined with Irbesartan and Pancreatic Kininogenase in the Treatment for Early Diabetic Nephropathy[J].Western Journal of Traditional Chinese Medicine,2013,26(06):68.
[2]王学琦,李丰华,张荣华,等.温肾汤治疗早期糖尿病肾病80例[J].西部中医药,2013,26(09):62.
　WANG Xueqi,LI Fenghua,ZHANG Ronghua,et al.WenShenTang for 80 Cases of Early Diabetic Nephropathy[J].Western Journal of Traditional Chinese Medicine,2013,26(06):62.
[3]任芳,徐厚谦△.黄芪注射液治疗糖尿病肾病有效性及安全性的系统评价[J].西部中医药,2014,27(01):77.
　REN Fang,XU Houqian.Systematic Review of the Effectiveness and Safety of HuangQi Injection in Treating Diabetic Nephropathy[J].Western Journal of Traditional Chinese Medicine,2014,27(06):77.
[4]丁夏楠,许筠△,苏建平,等.益肾逐瘀方治疗糖尿病肾病蛋白尿37例[J].西部中医药,2014,27(04):96.
　DING Xianan,XU Jun,SU Jianping,et al.Treatment for Proteinuria of 37 Patients with Diabetic Nephropathy by Kidney-invigorating Stagnation-dispelling Prescription[J].Western Journal of Traditional Chinese Medicine,2014,27(06):96.
[5]肖远莉.循证护理的优效性及影响因素分析———来自终末期糖尿病肾病患者血液透析的证据[J].西部中医药,2014,27(08):127.
[6]刘涛.缬沙坦联合复方丹参滴丸对早期2型糖尿病肾病患者尿微量白蛋白的影响[J].西部中医药,2015,28(05):106.
[7]连琯,史晓伟.当归补血汤合金水宝治疗早期糖尿病肾病16例临床观察[J].西部中医药,2013,26(06):68.
　LIAN Guan,SHI Xiaowei.Clinical Observation on DangGui BuXueTang and JinShuiBao in Treating 16 Cases of Early Diabetic Nephropathy[J].Western Journal of Traditional Chinese Medicine,2013,26(06):68.
[8]任芳,徐厚谦△.黄芪注射液治疗糖尿病肾病随机对照试验报告质量评价[J].西部中医药,2013,26(12):1.
　REN Fang,XU Houqian.Quality Evaluation of the Report for Randomized Controlled Trials of HuangQi Injection in Treating Diabetic Nephropathy[J].Western Journal of Traditional Chinese Medicine,2013,26(06):1.
[9]朱苗蕊,指导：金智生.糖脂平治疗早期糖尿病肾病60例疗效观察*[J].西部中医药,2013,26(03):74.
　ZHU Miaorui,Director: JIN Zhisheng.Clinical Observation on TangZhiPing in Treating 60 Cases of Early Diabetic Nephropathy[J].Western Journal of Traditional Chinese Medicine,2013,26(06):74.
[10]马天寿.血塞通联合西药治疗糖尿病肾病80例[J].西部中医药,2013,26(08):96.
　MA Tianshou.XueSaiTong Injection and Western Medicine in Treating 80 Cases of Diabetic Nephropathy[J].Western Journal of Traditional Chinese Medicine,2013,26(06):96.

备注/Memo

备注/Memo:
王永军（1970—），硕士学位，主任医师。研究方向：心、肾疾病的中医药防治。河北省2018年度医学科学研究重点课题（20180677）。
更新日期/Last Update: 2022-06-24